Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 07:36:34 2026-04-14 EDT			5-day change	1st Jan Change
247.18 ^DKK	+3.75%		+5.38%	-23.83%

06:44am	Novo Nordisk Receives UK Regulator Approval for Single-Dose 7.2mg of Wegovy	MT
06:26am	Wegovy Maker Novo Nordisk Strikes Deal With OpenAI to Speed Up Drug Discovery -- Update	DJ

Press Releases

02:00am	Novo Nordisk and OpenAI partner to transform how medicines are discovered and delivered	GL
04-13	Novo Nordisk A/S - share repurchase programme	GL
04-12	Novo Nordisk A/S : 2025 ( novo nordisk modern slavery statement 2025 )	PU
04-09	Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU	GL
04-07	Novo Nordisk A/S – Share repurchase programme	GL
04-02	Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs	AQ
04-01	FDA approves Eli Lilly's GLP-1 weight-loss pill	AQ
04-01	FDA grants speedy approval to Eli Lilly's weight-loss pill for obesity	AQ
04-01	LifeMD Offers Novo Nordisk's Industry-First Wegovy Telehealth Subscription Program	AQ
03-30	Novo Nordisk A/S - share repurchase programme	GL
03-28	Novo Nordisk A/S : Articles of Association 2026 (English) ( novo nordisk articles of association 2026 )	PU
03-27	Novo Nordisk's FDA-Approved GLP-1s Now Available with Hims & Hers	AQ
03-27	Articles of Association for Novo Nordisk A/S 2026	GL
03-26	Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes	GL
03-26	Resolutions from the Annual General Meeting of Novo Nordisk A/S	GL
03-26	Novo Nordisk A/S, Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes	AQ
03-25	Novo Nordisk A/S: Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes	GL
03-23	Novo Nordisk A/S - share repurchase programme	GL
03-19	Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss	GL
03-16	Novo Nordisk A/S - share repurchase programme	GL
03-12	WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards Strengthening Health Systems for Cardio-Renal-Metabolic Diseases	AQ
03-10	Hims & Hers shares rise 50 per cent after Novo Nordisk withdraws lawsuit	AQ
03-09	Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration	AQ
03-09	Hims & Hers agrees to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending suit	AQ
03-09	Novo Nordisk A/S - share repurchase programme	GL